Europe Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: 2022-12-24
- Report ID: 143411
- Pages: 225
-
Format:
Short Description
Europe Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells.
NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease.
The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity.
Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth.
Market Segmentation:
Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel.
On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies
On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.
On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others.
On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes
On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others.
Market Players
The key market players for natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 THERAPEUTICS LIFELINE CURVE 41
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.9 DBMR MARKET POSITION GRID 43
2.10 SECONDARY SOURCES 45
2.11 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
3.1 EPIDEMIOLOGY 51
3.2 PESTEL ANALYSIS 52
3.3 PORTERS FIVE FORCES MODEL 53
3.4 INDUSTRIAL INSIGHTS: 54
3.5 PIPELINE ANALYSIS 56
4 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 57
5 MARKET OVERVIEW 59
5.1 DRIVERS 61
5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 61
5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 61
5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 62
5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 62
5.2 RESTRAINTS 63
5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 63
5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 63
5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 64
5.3 OPPORTUNITIES 65
5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 65
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 65
5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 66
5.4 CHALLENGES 66
5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 66
5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 67
5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 67
6 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 69
6.1 OVERVIEW 70
6.2 NK CELL THERAPIES 73
6.3 NK CELL DIRECTED ANTIBODIES 73
7 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 75
7.1 OVERVIEW 76
7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 79
7.3 BISPECIFIC ANTIBODIES 80
8 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 81
8.1 OVERVIEW 82
8.2 CANCER 85
8.2.1 SOLID TUMORS 86
8.2.2 HEMATOLOGIC MALIGNANCIES 86
8.2.2.1 MULTIPLE MYELOMA 87
8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 87
8.2.2.3 LYMPHOMA 87
8.2.2.4 OTHERS 87
8.2.3 OTHERS 87
8.3 IMMUNOPROLIFERATIVE DISORDERS 87
8.4 ACUTE INFECTIOUS DISEASES 88
8.5 GASTROINTESTINAL DISEASES 88
8.6 OTHERS 89
9 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 91
9.1 OVERVIEW 92
9.2 HOSPITALS 95
9.3 SPECIALTY CLINICS 95
9.4 RESEARCH & ACADEMIC INSTITUTES 96
10 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 98
10.1 OVERVIEW 99
10.2 HOSPITAL PHARMACIES 102
10.3 DIRECT TENDER 102
10.4 OTHERS 103
11 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 104
11.1 EUROPE 105
11.1.1 GERMANY 112
11.1.2 FRANCE 114
11.1.3 ITALY 116
11.1.4 U.K. 118
11.1.5 SPAIN 120
11.1.6 NETHERLANDS 122
11.1.7 RUSSIA 124
11.1.8 SWITZERLAND 126
11.1.9 TURKEY 128
11.1.10 AUSTRIA 130
11.1.11 NORWAY 132
11.1.12 HUNGARY 134
11.1.13 LITHUANIA 136
11.1.14 IRELAND 138
11.1.15 POLAND 140
11.1.16 LUXEMBOURG 142
11.1.17 REST OF EUROPE 144
12 EUROPE NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 145
12.1 COMPANY SHARE ANALYSIS: EUROPE 145
13 SWOT ANALYSIS 146
14 COMPANY PROFILE 147
14.1 MERCK KGAA 147
14.1.1 COMPANY SNAPSHOT 147
14.1.2 RECENT FINANCIALS 147
14.1.3 PRODUCT PORTFOLIO 148
14.1.4 RECENT DEVELOPMENTS 148
14.2 BRISTOL-MYERS SQUIBB COMPANY 150
14.2.1 COMPANY SNAPSHOT 150
14.2.2 RECENT FINANCIALS 150
14.2.3 PRODUCT PORTFOLIO 151
14.2.4 RECENT DEVELOPMENTS 151
14.3 GLYCOSTEM 153
14.3.1 COMPANY SNAPSHOT 153
14.3.2 PRODUCT PORTFOLIO 153
14.3.3 RECENT DEVELOPMENTS 153
14.4 INNATE PHARMA, INC. 155
14.4.1 COMPANY SNAPSHOT 155
14.4.2 REVENUE ANALYSIS 155
14.4.3 PRODUCT PORTFOLIO 156
14.4.4 RECENT DEVELOPMENTS 156
14.5 REGENERON PHARMACEUTICALS INC. 158
14.5.1 COMPANY SNAPSHOT 158
14.5.2 RECENT FINANCIALS 158
14.5.3 PRODUCT PORTFOLIO 159
14.5.4 RECENT DEVELOPMENTS 159
14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 160
14.6.1 COMPANY SNAPSHOT 160
14.6.2 RECENT FINANCIALS 160
14.6.3 PRODUCT PORTFOLIO 161
14.6.4 RECENT DEVELOPMENTS 161
14.7 INMUNEBIO 162
14.7.1 COMPANY SNAPSHOT 162
14.7.2 REVENUE ANALYSIS 162
14.7.3 PRODUCT PORTFOLIO 163
14.7.4 RECENT DEVELOPMENTS 163
14.8 KIADIS PHARMA 165
14.8.1 COMPANY SNAPSHOT 165
14.8.2 REVENUE ANALYSIS 165
14.8.3 PRODUCT PORTFOLIO 166
14.8.4 RECENT DEVELOPMENTS 166
14.9 ACEPODIA INC. 168
14.9.1 COMPANY SNAPSHOT 168
14.9.2 PRODUCT PORTFOLIO 168
14.9.3 RECENT DEVELOPMENTS 168
14.10 AFFIMED GMBH 170
14.10.1 COMPANY SNAPSHOT 170
14.10.2 RECENT FINANCIALS 170
14.10.3 PRODUCT PORTFOLIO 171
14.10.4 RECENT DEVELOPMENTS 171
14.11 BIOHAVEN PHARMACEUTICALS 173
14.11.1 COMPANY SNAPSHOT 173
14.11.2 REVENUE ANALYSIS 173
14.11.3 PRODUCT PORTFOLIO 174
14.11.4 RECENT DEVELOPMENTS 174
14.12 BRINK BIOLOGICS, INC. 175
14.12.1 COMPANY SNAPSHOT 175
14.12.2 PRODUCT PORTFOLIO 175
14.12.3 RECENT DEVELOPMENT 175
14.13 CYTOVIA THERAPEUTICS 176
14.13.1 COMPANY SNAPSHOT 176
14.13.2 PRODUCT PORTFOLIO 176
14.13.3 RECENT DEVELOPMENTS 176
14.14 EMERCELL 178
14.14.1 COMPANY SNAPSHOT 178
14.14.2 PRODUCT PORTFOLIO 178
14.14.3 RECENT DEVELOPMENTS 178
14.15 FATE THERAPEUTICS 179
14.15.1 COMPANY SNAPSHOT 179
14.15.2 REVENUE ANALYSIS 179
14.15.3 PRODUCT PORTFOLIO 180
14.15.4 RECENT DEVELOPMENTS 180
14.16 GAMIDA CELL 182
14.16.1 COMPANY SNAPSHOT 182
14.16.2 PRODUCT PORTFOLIO 182
14.16.3 RECENT DEVELOPMENTS 183
14.17 ICELL GENE THERAPEUTICS 184
14.17.1 COMPANY SNAPSHOT 184
14.17.2 PRODUCT PORTFOLIO 184
14.17.3 RECENT DEVELOPMENT 184
14.18 IMMUNITYBIO, INC. 185
14.18.1 COMPANY SNAPSHOT 185
14.18.2 REVENUE ANALYSIS 185
14.18.3 PRODUCT PORTFOLIO 186
14.18.4 RECENT DEVELOPMENTS 186
14.19 MULTIMMUNE GMBH 187
14.19.1 COMPANY SNAPSHOT 187
14.19.2 PRODUCT PORTFOLIO 187
14.19.3 RECENT DEVELOPMENTS 187
14.20 NEKTAR 188
14.20.1 COMPANY SNAPSHOT 188
14.20.2 REVENUE ANALYSIS 188
14.20.3 PRODUCT PORTFOLIO 189
14.20.4 RECENT DEVELOPMENTS 189
14.21 NKARTA, INC. 190
14.21.1 COMPANY SNAPSHOT 190
14.21.2 PRODUCT PORTFOLIO 190
14.21.3 RECENT DEVELOPMENTS 190
14.22 PERSONGEN BIOTHERAPEUTICS 192
14.22.1 COMPANY SNAPSHOT 192
14.22.2 PRODUCT PORTFOLIO 192
14.22.3 RECENT DEVELOPMENTS 192
14.23 PHIO PHARMACEUTICALS 194
14.23.1 COMPANY SNAPSHOT 194
14.23.2 PRODUCT PORTFOLIO 194
14.23.3 RECENT DEVELOPMENTS 194
15 QUESTIONNAIRE 196
16 RELATED REPORTS 200
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
